Holen Sie sich die Stockscreener-App
0.9122
1.67%
-0.0155
Schlusskurs vom Vortag:
$0.9277
Offen:
$1
24-Stunden-Volumen:
108.84K
Relative Volume:
1.26
Marktkapitalisierung:
$5.76M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.29M
KGV:
-0.2286
EPS:
-3.99
Netto-Cashflow:
$-12.27M
1W Leistung:
-11.44%
1M Leistung:
-28.17%
6M Leistung:
-50.96%
1J Leistung:
-73.84%
1-Tages-Spanne:
$0.901
$1.00
1-Wochen-Bereich:
$0.90
$1.14
52-Wochen-Spanne:
$0.90
$5.00
Aprea Therapeutics Inc Stock (APRE) Company Profile
Firmenname
Aprea Therapeutics Inc
Sektor
Branche
Telefon
215-948-4119
Adresse
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Vergleichen Sie APRE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.9122 | 5.85M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-12-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-06-22 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-10-28 | Eingeleitet | JP Morgan | Neutral |
| 2019-10-28 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2019-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aprea Therapeutics Inc Aktie (APRE) Neueste Nachrichten
Aprea Therapeutics, Inc. announced that it expects to receive $3.055822 million in funding - marketscreener.com
Aprea Therapeutics raises $3.1 million in private placement - Investing.com
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules - The Manila Times
Aprea Therapeutics (Nasdaq: APRE) prices $3.1M private placement to extend cash runway into Q1 2027 - Stock Titan
Aprea Therapeutics (NASDAQ: APRE) registers 219,242 shares under 2019 equity plan - Stock Titan
Why Aprea Therapeutics Inc. stock is seen as undervaluedMarket Weekly Review & Growth Focused Investment Plans - Newser
Aprea Therapeutics, Inc. (NASDAQ:APRE): Is Breakeven Near? - simplywall.st
How Aprea Therapeutics Inc. stock performs in rising dollar environmentJuly 2025 Highlights & Free Low Drawdown Momentum Trade Ideas - Newser
Head and Neck Cancer Therapeutics Market | Global Market Analysis Report2035 - Fact.MR
Why Aprea Therapeutics Inc. stock could rally in 20252025 Top Decliners & Stepwise Swing Trade Plans - BỘ NỘI VỤ
Is Aprea Therapeutics Inc a good long term investmentRSI Overbought/Oversold & Learn From the Strategies of Institutions - earlytimes.in
Aprea Therapeutics Strengthens Patent Portfolio to Advance Oncology Innovation - MSN
Aprea Advances Dual DDR Programs as Early Signals of Drug Activity Strengthen - MSN
Why Aprea Therapeutics Inc. stock could outperform in 2025July 2025 Institutional & Free Weekly Chart Analysis and Trade Guides - newser.com
Can Aprea Therapeutics Inc. stock sustain free cash flow growthWatch List & Weekly Momentum Picks - newser.com
How supply chain issues affect Aprea Therapeutics Inc. stockEarnings Overview Report & Weekly Watchlist of Top Performers - newser.com
Is Aprea Therapeutics Inc. stock a top momentum play2025 Macro Impact & Free Daily Entry Point Trade Alerts - newser.com
Tools to assess Aprea Therapeutics Inc.’s risk profileQuarterly Earnings Summary & Fast Exit and Entry Strategy Plans - newser.com
Will Aprea Therapeutics Inc. stock outperform value stocks2025 Valuation Update & Weekly High Return Opportunities - newser.com
Aprea Therapeutics (Nasdaq: APRE) Advances Cancer Pipeline as Maxim Group Sets $10 Price Target - Barchart.com
Is Aprea Therapeutics Inc. stock attractive after correction2025 Big Picture & Fast Gaining Stock Reports - newser.com
Is Aprea Therapeutics Inc. stock poised for growthJuly 2025 Big Picture & Low Drawdown Investment Ideas - newser.com
Is Aprea Therapeutics Inc. stock attractive for growth ETFsWeekly Trend Report & Community Trade Idea Sharing Platform - newser.com
Finanzdaten der Aprea Therapeutics Inc-Aktie (APRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):